for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genscript Biotech Corp

1548.HK

Latest Trade

15.98HKD

Change

-0.58(-3.50%)

Volume

7,570,000

Today's Range

15.90

 - 

16.86

52 Week Range

10.60

 - 

21.70

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Legend Biotech Announces Chief Executive Officer Transition

Aug 2 (Reuters) - Legend Biotech Corp <LEGN.O>::LEGEND BIOTECH ANNOUNCES CHIEF EXECUTIVE OFFICER TRANSITION.BOARD OF DIRECTORS HAS APPOINTED FRANK ZHANG TO SERVE AS CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY.ZHANG WILL SUCCEED YUAN XU, WHO HAS RESIGNED FROM HER POSITION AS CHIEF EXECUTIVE OFFICER FOR PERSONAL REASONS.XU HAS ALSO RESIGNED FROM THE BOARD OF DIRECTORS OF LEGEND BIOTECH.LEGEND BIOTECH-CO’S STRATEGIC PARTNER JANSSEN BIOTECH EXPECTS TO INITIATE BLA FILING FOR LEAD CELL THERAPY PRODUCT JNJ-4528 TO FDA BY END OF 2020.LEGEND BIOTECH-EXPECTS MARKETING AUTHORIZATION APPLICATION WILL BE SUBMITTED TO THE EUROPEAN MEDICINES AGENCY IN EARLY 2021.ZHANG WILL CONTINUE TO SERVE AS CHAIRMAN OF LEGEND BIOTECH’S BOARD OF DIRECTORS.ZHANG HAS CONCURRENTLY STEPPED DOWN AS CHIEF EXECUTIVE OFFICER OF GENSCRIPT, LEGEND BIOTECH’S MAJORITY SHAREHOLDER.

GenScript Publishes Clinical Data On Method For Detecting COVID-19 Neutralizing Antibodies In Nature Biotechnology

July 23 (Reuters) - Genscript Biotech Corp <1548.HK>::GENSCRIPT ANNOUNCES PUBLICATION OF CLINICAL DATA ON NEW METHOD FOR DETECTING COVID-19 NEUTRALIZING ANTIBODIES IN NATURE BIOTECHNOLOGY.GENSCRIPT BIOTECH CORP - CPASS SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT CURRENTLY UNDER REVIEW FOR EUA WITH U.S. FDA.GENSCRIPT BIOTECH - CPASS TEST WAS ABLE TO DETECT NEUTRALIZING ANTIBODIES FROM PATIENTS WITH 95%-100% SENSITIVITY AND 99.93% SPECIFICITY.

Genscript Biotech Says An Executive Director Agreed To Sell 15 Mln Shares Of Co

June 16 (Reuters) - Genscript Biotech Corp <1548.HK>::AN EXECUTIVE DIRECTOR AGREED TO SELL 15 MILLION SHARES OF CO.THE EXECUTIVE DIRECTOR & INFINI CAPITAL MANAGEMENT ENTERED SHARE TRANSFER AGREEMENT.SHARES SOLD AT HK$14.16 PER SHARE FOR AN AGGREGATE CONSIDERATION OF HK$212.4 MILLION.EXECUTIVE DIRECTOR EXERCISED SHARE OPTIONS TO SUBSCRIBE FOR 15 MILLION SHARES GRANTED UNDER PRE-IPO SHARE OPTION SCHEME.

Genscript Biotech Says Wang Luquan To Sell 5 Mln Shares To Zhang Xiaolei At HK$17.32/Share

June 10 (Reuters) - Genscript Biotech Corp <1548.HK>::WANG LUQUAN TO SELL THROUGH GS CORP TO ZHANG XIAOLEI 5 MILLION SHARES AT HK$17.32/SHARE.SALE SHARES REPRESENT ABOUT 0.26% OF TOTAL ISSUED SHARE CAPITAL OF CO.WANG WILL REMAIN AS ONE OF CO'S CONTROLLING SHAREHOLDERS.

Genscript Biotech Updates On Separate Listing Of Legend Biotech Corp On Nasdaq Global Market

June 5 (Reuters) - Genscript Biotech Corp <1548.HK>::UPDATES ON PROPOSED SPIN-OFF & SEPARATE LISTING OF LEGEND BIOTECH CORP ON NASDAQ GLOBAL MARKET.TRADING IN ADSS OF LEGEND BIOTECH TO COMMENCE ON 5 JUNE.LEGEND BIOTECH'S INITIAL PUBLIC OFFER PRICE WAS FIXED AT US$23.00 PER ADS.EACH ADS WILL REPRESENT 2 LEGEND BIOTECH SHARES.18.4 MILLION ADSS WILL BE ISSUED BY LEGEND BIOTECH REPRESENTING ABOUT 12.7% OF ITS ISSUED SHARE CAPITAL.

Genscript Files For Emergency Use Authorization Of Rapid Sars-Cov-2 Antibody Detection Kit

June 3 (Reuters) - Genscript Biotech Corp <1548.HK>::GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT.GENSCRIPT BIOTECH - HAS FILED FOR EUA WITH U.S. FDA TO MARKET ITS CPASS SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT.

Genscript Biotech Says Legend Biotech Filed Registration Statement For IPO

May 29 (Reuters) - Genscript Biotech Corp <1548.HK>::LEGEND BIOTECH FILED REGISTRATION STATEMENT FOR IPO OF 18.4 MILLION NEW ADSS IN PRICE RANGE BETWEEN US$18.00 AND US$20.00.IF OFFER PRICE IS FIXED AT US$19.00 PER ADS,CO ESTIMATES NET PROCEEDS WILL BE ABOUT US$321.9 MILLION..

Genscript Biotech Updates On Phase 1B/2 Cartitude-1 Study Evaluating JNJ-68284528

May 14 (Reuters) - Genscript Biotech Corp <1548.HK>::UPDATES ON PHASE 1B/2 CARTITUDE-1 STUDY EVALUATING EFFICACY & SAFETY OF JNJ-68284528.LONGER-TERM FOLLOW-UP RESULTS FROM PHASE 1B PORTION OF STUDY SHOW ALL PATIENTS RESPONDED TO TREATMENT.LONGER-TERM FOLLOW-UP RESULTS FROM PHASE 1B PORTION SHOW RESPONSES WERE DEEP & DURABLE WITH 86% OF PATIENTS.

Genscript Biotech Corp Says On 11 April, Rising Arrow Enterprise Entered Purchase Agreement

April 14 (Reuters) - Genscript Biotech Corp <1548.HK>::GENSCRIPT BIOTECH CORP -ON 11 APRIL, RISING ARROW ENTERPRISE LTD ENTERED INTO PURCHASE AGREEMENT AS AN ADDITIONAL PARTY.GENSCRIPT BIOTECH CORP - LEGEND CAYMAN TO SELL & ISSUE 1.3 MILLION ADDITIONAL SERIES A PREFERENCE SHARES AT AGGREGATE CONSIDERATION OF ABOUT US$10 MILLION.

Genscript Biotech Says Unit Sells 19.3 Million Series A Preference Shares For US$150.5 Mln

March 31 (Reuters) - Genscript Biotech Corp <1548.HK>::UNIT SELLS 19.3 MILLION SERIES A PREFERENCE SHARES FOR US$150.5 MILLION TO JOHNSON & JOHNSON INNOVATION, LAV BIOSCIENCES FUND & OTHERS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up